Impatients N.V. trading as myTomorrows
5
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 5 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
Role: collaborator
Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2
Role: collaborator
Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)
Role: lead
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
Role: lead
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
Role: lead
All 5 trials loaded